Biogen Inc (BIIB)

Currency in USD
124.99
-3.70(-2.88%)
Closed·
After Hours
126.33+1.34(+1.07%)
·
BIIB Scorecard
Full Analysis
10 analysts have revised their earnings downwards for the upcoming period
Earnings results expected in 11 days
Fair Value
Day's Range
124.68129.58
52 wk Range
110.04236.48
Key Statistics
Prev. Close
128.69
Open
129.37
Day's Range
124.68-129.58
52 wk Range
110.04-236.48
Volume
1.52M
Average Vol. (3m)
1.48M
1-Year Change
-44.79%
Book Value / Share
115.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIIB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
172.51
Upside
+38.02%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Biogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Biogen Inc Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Employees
7605

Biogen Inc SWOT Analysis


Market Valuation
With price targets ranging from $115 to $206, Biogen's stock appears undervalued at $128.39, presenting potential upside amid strategic initiatives
Pipeline Potential
Explore Biogen's R&D focus on genetic medicine and targeted therapies, with analysts divided on its ability to offset declining MS revenues
Financial Health
Despite market volatility, Biogen maintains strong profitability with a 76% gross margin and 13% free cash flow yield, signaling resilience
Neuroscience Pionee
Biogen, a leader in neuroscience and rare diseases, faces challenges in its MS franchise while pursuing growth in Alzheimer's and genetic medicine
Read full SWOT analysis

Biogen Inc Earnings Call Summary for Q1/2025

  • Biogen's Q1 2025 EPS of $3.02 beat $2.96 forecast; revenue of $2.43B exceeded $2.23B expectation, driving 1.49% stock increase
  • Revenue grew 6% YoY to $2.4B despite challenges; company projects mid-single-digit revenue decline for 2025
  • 2025 non-GAAP EPS guidance set at $14.50-$15.50; five phase three studies to be initiated this year
  • CEO describes Biogen as 'tale of two companies,' balancing established products with innovative therapies in Alzheimer's and rare diseases
  • Company faces competitive pressures in MS market and uncertain dynamics in Alzheimer's treatment space
Last Updated: 05/01/2025, 09:56 AM
Read Full Transcript

Compare BIIB to Peers and Sector

Metrics to compare
BIIB
Peers
Sector
Relationship
P/E Ratio
12.4x2.7x−0.5x
PEG Ratio
0.470.050.00
Price / Book
1.1x2.6x2.6x
Price / LTM Sales
1.9x8.5x3.2x
Upside (Analyst Target)
32.0%66.4%44.3%
Fair Value Upside
Unlock6.4%6.6%Unlock

Analyst Ratings

18 Buy
18 Hold
1 Sell
Ratings:
37 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 172.51
(+38.02% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
3.02 / 2.96
Revenue / Forecast
2.43B / 2.23B
EPS Revisions
Last 90 days

BIIB Income Statement

People Also Watch

315.57
CDNS
-1.65%
60.72
ON
+2.21%
34.54
CMCSA
-0.46%
365.79
ADBE
-0.18%
172.41
NVDA
-0.34%

FAQ

What Is the Biogen (BIIB) Stock Price Today?

The Biogen stock price today is 124.99

What Stock Exchange Does Biogen Trade On?

Biogen is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Biogen?

The stock symbol for Biogen is "BIIB."

What Is the Biogen Market Cap?

As of today, Biogen market cap is 18.31B.

What Is Biogen's Earnings Per Share (TTM)?

The Biogen EPS (TTM) is 10.14.

When Is the Next Biogen Earnings Date?

Biogen will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is BIIB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biogen Stock Split?

Biogen has split 2 times.

How Many Employees Does Biogen Have?

Biogen has 7605 employees.

What is the current trading status of Biogen (BIIB)?

As of Jul 20, 2025, Biogen (BIIB) is trading at a price of 124.99, with a previous close of 128.69. The stock has fluctuated within a day range of 124.68 to 129.58, while its 52-week range spans from 110.04 to 236.48.

What Is Biogen (BIIB) Price Target According to Analysts?

The average 12-month price target for Biogen is USD172.50581, with a high estimate of USD260 and a low estimate of USD115. 18 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +38.02% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.